Showing results (41-50 of 225) with videos related to

Sort By:
Pageof 23
Journal of Cellular and Molecular Medicine|July 6, 2010
Molecular markers in circulating tumour cells from metastatic colorectal cancer patientsPaola Gazzaniga, Angela Gradilone, Arianna Petracca, et al.
Anti-Cancer Drugs|October 28, 2016
Prognostic role of the cumulative toxicity in patients affected by metastatic renal cells carcinoma and treated with first-line tyrosine kinase inhibitorsRoberto Iacovelli, Elena Verri, Maria Cossu Rocca, et al.
Cancer Treatment Reviews|July 26, 2016
The prospect of precision therapy for renal cell carcinomaChiara Ciccarese, Matteo Brunelli, Rodolfo Montironi, et al.
European Journal of Cancer (Oxford, England : 1990)|July 15, 2015
The incidence and relative risk of cardiovascular toxicity in patients treated with new hormonal agents for castration-resistant prostate cancerRoberto Iacovelli, Elena Verri, Maria Cossu Rocca, et al.
Urologia|December 20, 2022
Management of metastatic urothelial carcinoma: Current approach, emerging agents, and future perspectivesRoberto Iacovelli, Carlo Maria Cicala, Chiara Ciccarese, et al.
Anticancer Research|May 2, 2018
Relationship and Predictive Role of the Dual Expression of FGFR and IL-8 in Metastatic Renal Cell Carcinoma Treated with Targeted AgentsRoberto Iacovelli, Michele DE Tursi, Claudia Mosillo, et al.
Future Oncology (London, England)|July 24, 2014
Targeted therapies in advanced renal cell carcinoma: the role of metastatic sites as a prognostic factorPaolo Grassi, Elena Verzoni, Luca Porcu, et al.
British Journal of Clinical Pharmacology|August 29, 2013
Incidence and relative risk of hepatic toxicity in patients treated with anti-angiogenic tyrosine kinase inhibitors for malignancyRoberto Iacovelli, Antonella Palazzo, Giuseppe Procopio, et al.
Expert Opinion on Biological Therapy|August 5, 2018
Necitumumab in the treatment of non-small-cell lung cancer: clinical controversiesVincenzo di Noia, Ettore D'Argento, Sara Pilotto, et al.
Clinical Genitourinary Cancer|August 28, 2014
Everolimus and temsirolimus are not the same second-line in metastatic renal cell carcinoma. A systematic review and meta-analysis of literature dataRoberto Iacovelli, Matteo Santoni, Elena Verzoni, et al.
Pageof 23